Seattle Genetics discontinuing lintuzumab in AML
This article was originally published in Scrip
Executive Summary
Seattle Genetics is discontinuing the development of its anti-CD33 monoclonal antibody lintuzumab (SGN-33) after it failed to show a survival benefit in a Phase IIb trial in older patients with acute myeloid leukaemia (AML).